Genscript Biotech (01548): Legend Biotech Unveils Multiple Research Findings at 2026 ASCO Annual Meeting

Stock News

May 22

Genscript Biotech (01548) announced that its associate company, Legend Biotech Corporation (Legend, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares), submitted a Form 6-K to the U.S. Securities and Exchange Commission (SEC) and issued a press release on May 21, 2026 (New York Time) (before the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. A featured rapid oral presentation will highlight initial Phase 1 clinical data for LB2102, an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel, ciltacabtagene autoleucel) will be presented.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1192318750"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192318750\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192318750?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 08:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192318750","market":"hk","top_or_hot":-1,"title":"Genscript Biotech (01548): Legend Biotech Unveils Multiple Research Findings at 2026 ASCO Annual Meeting","media":"Stock News","content":"<p>Genscript Biotech (01548) announced that its associate company, Legend Biotech Corporation (Legend, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares), submitted a Form 6-K to the U.S. Securities and Exchange Commission (SEC) and issued a press release on May 21, 2026 (New York Time) (before the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. A featured rapid oral presentation will highlight initial Phase 1 clinical data for LB2102, an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel, ciltacabtagene autoleucel) will be presented.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech (01548): Legend Biotech Unveils Multiple Research Findings at 2026 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech (01548): Legend Biotech Unveils Multiple Research Findings at 2026 ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-22 08:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech (01548) announced that its associate company, Legend Biotech Corporation (Legend, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares), submitted a Form 6-K to the U.S. Securities and Exchange Commission (SEC) and issued a press release on May 21, 2026 (New York Time) (before the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. A featured rapid oral presentation will highlight initial Phase 1 clinical data for LB2102, an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel, ciltacabtagene autoleucel) will be presented.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"","article_id":"1192318750","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192318750","pubTimestamp":1779409307,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Genscript Biotech (01548) announced that its associate company, Legend Biotech Corporation (Legend, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1141":"生命科学工具和服务","01548":"金斯瑞生物科技","BK1583":"高瓴概念","BK1576":"医药外包概念","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"金斯瑞生物(01548)：传奇生物在2026年ASCO年会上公布多项研究成果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech (01548) announced that its associate company, Legend Biotech Corporation (Legend, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares), submitted a Form 6-K to the U.S. Securities and Exchange Commission (SEC) and issued a press release on May 21, 2026 (New York Time) (before the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. A featured rapid oral presentation will highlight initial Phase 1 clinical data for LB2102, an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel, ciltacabtagene autoleucel) will be presented.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}